Abstract Number: 2497 • ACR Convergence 2023
Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease defined by its heterogeneity and cycles of flares and remissions. Owing to non-specific or incomplete…Abstract Number: 2589 • ACR Convergence 2023
Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus
Background/Purpose: Chronic glucocorticoid (GC) morbidity is rarely captured as a standardized clinical outcome in pediatric rheumatic conditions. The pediatric glucocorticoid toxicity index (pGTI) (Brogan et…Abstract Number: 0033 • ACR Convergence 2023
A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients
Background/Purpose: Gene expression analysis coupled with machine learning (ML) holds the promise of identifying subsets of patients with heterogeneous diseases, such as systemic lupus erythematosus…Abstract Number: 0141 • ACR Convergence 2023
In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis
Background/Purpose: Systemic lupus erythematosus is a chronic inflammatory disorder that significantly burdens our health system. The study aimed to understand the difference in in-patient outcomes…Abstract Number: 0192 • ACR Convergence 2023
Demographic and Clinical Factors That Contribute to Clinical Study Enrollment in Systemic Lupus Erythematosus
Background/Purpose: Participation in clinical trials is part of treatment for many patients with chronic diseases. However, patients with systemic lupus erythematosus (SLE), especially those of…Abstract Number: 0546 • ACR Convergence 2023
Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis
Background/Purpose: Lupus nephritis (LN) is regarded as one of the most severe manifestations of systemic lupus erythematosus (SLE). This inflammation in the kidneys may lead…Abstract Number: 0563 • ACR Convergence 2023
Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: Neutrophil gelatinase-associated lipocalin (NGAL) is an acute-phase glycoprotein increased by inflammatory stimuli, oxidative stress, and tissue injury. Although NGAL is associated with global and…Abstract Number: 0581 • ACR Convergence 2023
Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
Background/Purpose: Detection of autoantibodies is key for the identification and prognosis of patients with connective tissue diseases (CTD); however, some current testing methods are manual,…Abstract Number: 0598 • ACR Convergence 2023
Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…Abstract Number: 0890 • ACR Convergence 2023
Specificity of Brain-Intrinsic and Hematopoietic-Derived Mechanisms in Mediating Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple end organs including the brain. Despite a prevalence of over 50% in…Abstract Number: 0910 • ACR Convergence 2023
17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…Abstract Number: 0931 • ACR Convergence 2023
Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation
Background/Purpose: Recently mitochondria have been recognized as a key player in the pathogenesis of systemic lupus erythematosus (SLE). Given that N6-methyladenosine (m6A) modifications can regulate…Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…Abstract Number: 1356 • ACR Convergence 2023
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Women with systemic rheumatic diseases (SRDs), particularly those with SLE, may be more vulnerable to HPV infection and HPV-related cervical cancer. However, HPV testing…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 150
- Next Page »